Telehealth Platforms Are Moving GLP-1 Drugs Into Addiction Care Before the Evidence Catches Up
Telehealth has accelerated access to GLP-1 drugs in ways that now extend beyond diabetes and obesity, and some platforms are promoting them for substance use disorder despite the absence of an FDA-approved indication. The result is a fast-moving clinical experiment playing out in routine care, with patients receiving off-label prescriptions through fragmented channels that can sit far outside the medical home.
The concern is not simply that clinicians are prescribing off-label. Off-label use is a standard part of medicine when evidence, physiology, and patient need align. The larger problem is the setting: a telehealth model can separate prescribing from longitudinal monitoring, complicate coordination with addiction treatment, and make it harder to detect adverse effects or treatment failures before they become clinically meaningful. In addiction medicine, where relapse, polysubstance use, psychiatric comorbidity, and social instability are common, that fragmentation carries obvious consequences.
A single sentence captures the tension. Patients may gain access faster, but they may also lose the clinical scaffolding needed to use these medications safely.
Why GLP-1 Interest Has Reached Addiction Medicine
The appeal of GLP-1 receptor agonists in addiction care is biologically understandable. These drugs alter satiety signaling and reward pathways, and that has prompted interest in whether they could blunt craving or reduce compulsive substance use. Early signals across several conditions have encouraged investigators and clinicians to ask whether a class best known for metabolic effects might also influence reward-driven behavior.
That scientific curiosity is legitimate. What is not established is whether telehealth promotion has outrun the evidence base. Addiction treatment is not the same as weight management or glycemic control. The therapeutic goal is not only symptom reduction but also safety in a population that may already be taking sedatives, stimulants, opioids, alcohol, or psychiatric medications, often with limited continuity of care. If a medication is being used off-label for addiction, the threshold for monitoring should rise, not fall.
In practice, the clinical questions pile up quickly. Which patients are being selected? Which substance use disorders are being targeted? How are withdrawal, appetite suppression, nausea, dehydration, and psychiatric symptoms being followed? How are clinicians determining whether the drug is helping, masking risk, or simply being layered onto an already unstable treatment plan?
Fragmented Care Creates Blind Spots at the Bedside
Telehealth can improve access, especially for patients who live far from addiction specialists or who avoid in-person treatment because of stigma. But the same convenience can weaken the link between prescribing and the broader care team. Primary care clinicians, psychiatrists, addiction specialists, pharmacists, and counselors may not see the full medication picture if treatment is initiated through a standalone online platform.
That matters because off-label GLP-1 prescribing for addiction does not occur in a vacuum. Patients with substance use disorders often have medical complexity that includes malnutrition risk, unstable housing, depression, liver disease, pancreatitis risk factors, and medication nonadherence. A remote workflow may not capture enough of that context to assess whether a GLP-1 is appropriate, contraindicated, or simply premature.
The safety concern also extends to follow-up. Dose escalation, side effect surveillance, and reassessment of benefit all depend on repeated contact. A telehealth model can offer follow-up, but it can also encourage transactional prescribing if the platform’s incentives favor rapid access over slow, multidisciplinary care. In addiction medicine, speed has value only when it does not outrun observation.
Unknown Risks Remain a Real Clinical Barrier
The abstract’s central warning is straightforward: experts worry about exposing patients to unknown risks. That language is careful for a reason. The risk profile of GLP-1 drugs in people being treated for addiction has not been fully defined in the context described here, and any expansion into this area should be judged against what is actually known, not what is hoped for.
Nausea, vomiting, poor oral intake, and dehydration are familiar adverse effects of the class. In patients with substance use disorder, those effects may be harder to absorb clinically because they can overlap with withdrawal syndromes, gastrointestinal illness, or medication side effects from other treatments. If a patient is also using alcohol or opioids, appetite suppression and reduced intake may compound frailty or interfere with recovery. If psychiatric illness is present, the clinical picture can become even harder to interpret.
There is also a systems-level risk. When prescribing happens through an online service that sits apart from the patient’s ongoing clinicians, adverse events may be recognized late, documented inconsistently, or never connected back to the original prescription pathway. The drug then becomes not only off-label, but also off-network in a way that obscures accountability.
Addiction Treatment Needs More Than a Prescription Funnel
The most consequential issue may be the mismatch between a high-complexity condition and a low-friction prescribing model. Substance use disorder care often requires counseling, behavioral treatment, management of co-occurring psychiatric illness, harm reduction, and repeated reassessment of readiness for change. A medication alone rarely solves that. When telehealth platforms market a GLP-1 as a treatment option for addiction without the surrounding infrastructure, they risk reducing a chronic, relapsing condition to a prescription transaction.
There is a narrow circumstance in which a remote model could still work well: if it functions as a bridge into coordinated care rather than a substitute for it. That would require careful patient selection, transparent discussion of uncertainty, communication with other clinicians, and monitoring that is robust enough to catch adverse effects and assess real benefit. Without those elements, the model invites a familiar problem in modern medicine—easy access paired with thin follow-through.
The central unanswered issue is not whether GLP-1 drugs could someday have a role in addiction medicine. It is whether the current wave of telehealth prescribing is being deployed in advance of the evidence, with too little oversight and too little continuity to protect the very patients it intends to help.